FI110408B - Menetelmä rakennetta antavan matriisin käsittävän farmaseuttisen koostumuksen valmistamiseksi - Google Patents

Menetelmä rakennetta antavan matriisin käsittävän farmaseuttisen koostumuksen valmistamiseksi Download PDF

Info

Publication number
FI110408B
FI110408B FI935314A FI935314A FI110408B FI 110408 B FI110408 B FI 110408B FI 935314 A FI935314 A FI 935314A FI 935314 A FI935314 A FI 935314A FI 110408 B FI110408 B FI 110408B
Authority
FI
Finland
Prior art keywords
matrix
saponin
process according
cholesterol
eller
Prior art date
Application number
FI935314A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935314A (fi
FI935314A0 (fi
Inventor
Bror Morein
Karin Loevgren
Original Assignee
Iscovent Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iscovent Ab filed Critical Iscovent Ab
Publication of FI935314A publication Critical patent/FI935314A/fi
Publication of FI935314A0 publication Critical patent/FI935314A0/fi
Application granted granted Critical
Publication of FI110408B publication Critical patent/FI110408B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
FI935314A 1991-05-31 1993-11-29 Menetelmä rakennetta antavan matriisin käsittävän farmaseuttisen koostumuksen valmistamiseksi FI110408B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9101665A SE502569C2 (sv) 1991-05-31 1991-05-31 Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
SE9101665 1991-05-31
PCT/SE1992/000367 WO1992021331A1 (fr) 1991-05-31 1992-06-01 Excipients pharmaceutiques
SE9200367 1992-06-01

Publications (3)

Publication Number Publication Date
FI935314A FI935314A (fi) 1993-11-29
FI935314A0 FI935314A0 (fi) 1993-11-29
FI110408B true FI110408B (fi) 2003-01-31

Family

ID=20382906

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935314A FI110408B (fi) 1991-05-31 1993-11-29 Menetelmä rakennetta antavan matriisin käsittävän farmaseuttisen koostumuksen valmistamiseksi

Country Status (13)

Country Link
US (1) US5603958A (fr)
EP (1) EP0587659B1 (fr)
JP (1) JPH07500084A (fr)
KR (1) KR100227302B1 (fr)
AT (1) ATE152620T1 (fr)
AU (1) AU680807B2 (fr)
CA (1) CA2103447C (fr)
DE (1) DE69219600T2 (fr)
ES (1) ES2103946T3 (fr)
FI (1) FI110408B (fr)
NO (1) NO306539B1 (fr)
SE (1) SE502569C2 (fr)
WO (1) WO1992021331A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
EP0913095A4 (fr) * 1996-07-08 2000-02-23 Tomoya Aoyama Composition d'alimentation pour volaille
JP4546643B2 (ja) * 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
EP1121088B1 (fr) * 1998-10-14 2002-12-18 Cognis Deutschland GmbH & Co. KG Utilisation de sterols et de sterols esterifies de l'ordre du nanometre
IL146382A0 (en) * 1999-05-13 2002-07-25 American Cyanamid Co Adjuvant combination formulations
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
EP2011517A1 (fr) * 2001-04-04 2009-01-07 Nordic Vaccine Technology A/S Complexes liant les polynucléotiques comprenant des stérols et de la saponine
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
CA2472581C (fr) * 2002-01-15 2012-06-26 Trustees Of Dartmouth College Derives de bis-enone tricyclique et methodes d'utilisation
US20040033202A1 (en) * 2002-06-10 2004-02-19 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and novel sterol combinations
EP1545605B8 (fr) * 2002-10-02 2010-05-26 Nordic Vaccine A/S Composition vaccinale
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DK1718283T3 (da) 2004-01-22 2013-04-22 Univ Miami Topisk co-enzyme Q10 formuleringer og fremgangsmåder for anvendelse.
CN100339083C (zh) * 2004-02-24 2007-09-26 范敏华 一种黄体酮液体胶囊及其制备方法
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100398151C (zh) * 2005-02-18 2008-07-02 浙江大学 人参皂甙纳米微粒及其制备方法和用途
US20110098177A1 (en) * 2006-03-28 2011-04-28 Novus International Inc. Methods and compositions of plant micronutrients
US20080015218A1 (en) * 2006-07-12 2008-01-17 Novus International Inc. Antioxidant combinations for use in ruminant feed rations having a fat source
US8691843B2 (en) * 2006-07-12 2014-04-08 Novus International, Inc. Antioxidant combinations for use in ruminant feed rations
CN101594849A (zh) * 2006-11-17 2009-12-02 诺华丝国际股份有限公司 具有有机酸和脂肪酸的基质嵌入型组合物
US20080119552A1 (en) * 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
WO2008064133A1 (fr) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthèse et activités biologiques de nouveaux composés tricycliques-bis-énones (tbe)
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064132A2 (fr) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Triterpénoïdes synthétiques et bis-énones tricycliques pour une utilisation dans la stimulation de croissance osseuse et cartilagineuse
AU2007322424B2 (en) * 2006-11-20 2013-05-16 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
CA2823407C (fr) 2007-03-22 2016-10-18 Berg Pharma Llc Formulations topiques ayant une biodisponibilite amplifiee
BRPI0813484B1 (pt) * 2007-07-03 2018-10-09 Novus Int Inc composição seca com baixos níveis de carboidratos fermentáveis, método para passar um leitão do desmame para uma dieta de produtor final de engorda, ração de alimentação de leitão e alimento artificial
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US8404714B2 (en) * 2008-01-04 2013-03-26 Novus International, Inc. Combinations to improve animal health and performance
CN108434151A (zh) 2008-01-11 2018-08-24 里亚塔医药公司 合成三萜类化合物及用以治病之方法
WO2009126764A1 (fr) 2008-04-11 2009-10-15 Cytotech Labs, Llc Procédés et utilisation d'induction de l'apoptose dans des cellules cancéreuses
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
EA022588B1 (ru) 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
WO2009146218A2 (fr) 2008-04-18 2009-12-03 Reata Pharmaceuticals, Inc. Composés comprenant un pharmacore anti-inflammatoire et procédés d'utilisation
JP5758801B2 (ja) * 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ 単環式シアノエノンおよびその使用方法説明
JP2012526828A (ja) 2009-05-11 2012-11-01 バーグ バイオシステムズ，エルエルシー エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法
US20110020914A1 (en) * 2009-07-24 2011-01-27 Novus International Inc Methods for enhancing growth of organisms in an aqueous growth medium
ES2664793T3 (es) * 2010-03-12 2018-04-23 Berg Llc Formulaciones intravenosas de coenzima Q10 (CoQ10) y métodos de uso de las mismas
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
JP5932993B2 (ja) 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
EP2750683B2 (fr) * 2011-10-03 2021-01-06 Croda International PLC Nanoparticules, leur procédé de préparation et leur utilisation comme support pour des molécules amphipatiques ou hydrophobes dans des domaines de la médecine, comprenant le traitement du cancer et des composés alimentaires
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
CA3042123A1 (fr) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methodes de traitement du syndrome d'alport a l'aide d'un methyle de bardoxolone ou d'analogues de ce dernier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3775783D1 (de) * 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US5196192A (en) * 1988-05-31 1993-03-23 Biotechnology Australia Pty. Ltd. Actions of hormones
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5077057A (en) * 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity

Also Published As

Publication number Publication date
AU1925192A (en) 1993-01-08
WO1992021331A1 (fr) 1992-12-10
EP0587659A1 (fr) 1994-03-23
JPH07500084A (ja) 1995-01-05
NO934315L (no) 1994-01-26
DE69219600D1 (de) 1997-06-12
DE69219600T2 (de) 1997-10-02
US5603958A (en) 1997-02-18
SE9101665D0 (sv) 1991-05-31
EP0587659B1 (fr) 1997-05-07
ES2103946T3 (es) 1997-10-01
NO934315D0 (no) 1993-11-29
FI935314A (fi) 1993-11-29
SE9101665L (sv) 1992-12-01
FI935314A0 (fi) 1993-11-29
KR100227302B1 (ko) 1999-11-01
AU680807B2 (en) 1997-08-14
SE502569C2 (sv) 1995-11-13
CA2103447A1 (fr) 1992-12-01
ATE152620T1 (de) 1997-05-15
CA2103447C (fr) 1999-03-16
NO306539B1 (no) 1999-11-22

Similar Documents

Publication Publication Date Title
FI110408B (fi) Menetelmä rakennetta antavan matriisin käsittävän farmaseuttisen koostumuksen valmistamiseksi
US6589943B2 (en) Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
US20180104330A1 (en) Nanoparticles, Composed of Sterol and Saponin From Quillaja Saponaria Molina Process for Preparation and Use Thereof as Carrier for Amphipatic of Hydrophobic Molecules in Fields of Medicine Including Cancer Treatment and Food Related Compounds
US20080003293A1 (en) Use of Buckysome or Carbon Nanotube for Drug Delivery
JP2021516211A (ja) ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
Ma et al. A highly stable norcantharidin loaded lipid microspheres: preparation, biodistribution and targeting evaluation
KR20110039798A (ko) 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
WO2007078879A2 (fr) Compositions de lipopeptides et leurs procédés d'utilisation
AU583402B2 (en) Method for the production of a macromolecular carrier loaded with a biologically active substance
EP0634926A1 (fr) Composition a usage therapeutique ou diagnostique, et mode de preparation et d'utilisation
JP6772282B2 (ja) 抗癌薬の新規ナノ製剤及びその製造方法
WO2011120339A1 (fr) Formulation de microémulsion contenant de l'arctigénine
JP2004528366A (ja) 両親媒性ヘパリン誘導体の粘膜吸収を増加させるための製造方法
JP3779744B2 (ja) 単糖誘導体または単糖誘導体を含有する脂肪乳剤
JPS5857321A (ja) 抗癌剤
Samy et al. Complement activation assay and invivo evaluation of silymarin loaded liver targeting liposome
CN109663132B (zh) 一种新型抗癌药物纳米制剂及其制备方法
EP3364953B1 (fr) Nouvelles formulations liposomales pour administration hépatique de médicaments par voie orale
CN106389332A (zh) 一种长循环的氧化石蒜碱有机酸复合物新制剂
AMAGAYA et al. Gastrointestinal absorption of paeoniflorin in germ—free rats
JP2023533797A (ja) 脂質複合体を含む経口医薬組成物
Madhusudhan et al. Improved oral absorption of carbamazepine from 1-O-alkylglycerol stabilized o/w nanoemulsions
Rogers et al. Alternative methods of drug delivery